Needham Reiterates Buy on Viridian Therapeutics, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a Buy rating on Viridian Therapeutics (NASDAQ:VRDN) and maintained a $30 price target.

February 28, 2024 | 12:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Serge Belanger reiterates a Buy rating on Viridian Therapeutics and maintains a $30 price target.
The reiteration of a Buy rating and maintenance of a $30 price target by a reputable analyst like Serge Belanger from Needham is likely to instill confidence among investors and could positively influence Viridian Therapeutics' stock price in the short term. Analyst ratings, especially from well-regarded financial institutions, can significantly impact investor sentiment and stock prices.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100